Highest-materiality recent filing
Atea Q1 net loss $45.4M ($0.57/shr); HCV Phase 3 topline mid-2026
Net loss $45.4M vs $34.3M YoY; R&D spend rose to $41.1M on HCV Phase 3 and HEV preclinical.
Net loss of $42.0M ($0.53 diluted EPS) vs $31.2M ($0.37) in Q3 2024; R&D expenses rose to $38.3M.
Atea Q2 net loss $37.2M ($0.44/shr); cash $379.7M; repurchases shares; strategic review ongoing
Net loss of $37.2M ($0.44 diluted EPS) vs $40.5M loss in Q2 2024; R&D expense $32.3M, down $2.4M YoY.
Atea Pharma Q1 net loss narrows to $34.3M; cash $425M; Phase 3 HCV trial enrolling
Net loss $34.3M ($0.40/share) vs $63.2M ($0.75) in Q1 2024; R&D expense down 49% to $29.6M.
Atea appoints Howard Berman to board, authorizes $25M buyback after activist settlement
Howard H. Berman (Coya Therapeutics founder) appointed as Class III director effective after 2025 annual meeting; will serve as observer until then.
Atea Pharmaceuticals receives director nominations from two stockholders for 2025 Annual Meeting
Bradley L. Radoff nominates Howard H. Berman, James P. Flynn, and Michael Torok.
Atea reports Q4/FY2024 results; cash at $454.7M; HCV Phase 3 starts April 2025
Net loss per share Q4 2024 improved to ($0.40) from ($0.47); full year net loss per share ($2.00) vs ($1.63).
Atea reports $454.7M cash, plans global Phase 3 HCV program starting Q1 2025
Cash, cash equivalents and marketable securities $454.7M at Dec 31, 2024; cash runway into 2028.
Atea Q3 net loss $31.2M (-$0.37/sh); COVID-19 Phase 3 fails, HCV topline Dec 2024
Net loss $31.2M ($0.37 diluted EPS) vs $33.1M loss ($0.40) YoY; cash $482.8M at Sept 30.
Atea reports Q2 net loss $40.5M; Phase 2 HCV data show 97% SVR12; Phase 3 COVID-19 trial due 2H24
Net loss of $40.5M for Q2 2024 (diluted EPS -$0.48) vs $28.2M loss in Q2 2023; cash balance $502.2M.
Atea Q1 2024 net loss $63.2M; Phase 3 COVID trial enrollment complete, results due 2H 2024
Net loss $63.2M ($0.75 per share) vs $35.5M ($0.43) in Q1 2023.
Atea Pharma Q2 net loss $28.2M; progresses COVID-19 & HCV trials
Net loss of $28.2M in Q2 2023 (EPS -$0.34) compared to $31.3M loss in Q2 2022.
Atea Q1 net loss $35.5M ($0.43/share); cash $620.5M; progresses bemnifosbuvir trials
Net loss of $35.5M ($0.43 diluted EPS) vs $42.1M ($0.51) in Q1 2022; no revenue.
Net loss of $34.4M ($0.41 loss per share) in Q4 2022 vs net income of $117.1M in Q4 2021; full year 2022 net loss $115.9M.
Atea Pharma Q2 net loss $31.3M; bemnifosbuvir enters late-stage COVID-19 trial
Net loss of $31.3M ($0.38 diluted loss per share) vs net income of $1.5M in Q2 2021; no collaboration revenue.
Net loss of $42.1M ($0.51 per diluted share) vs net income of $30.7M in Q1 2021; revenue $0 vs $65.985M due to Roche termination.
Full year 2021 net income $121.2M vs net loss $10.9M in 2020; revenue of $351.4M from Roche license termination.
Roche terminates license agreement for AT-527 with Atea; effective Feb 10, 2022
Roche sent termination notice on Nov 12, 2021; license ends Feb 10, 2022.
Atea reports Q3 net loss $28.2M; plans Phase 3 MORNINGSKY amendment with new primary endpoint
Net loss $28.2M for Q3 2021 vs $17.6M loss in Q3 2020; collaboration revenue $32.8M from Roche license.
On April 16, 2025, the Board appointed Howard H. Berman, Ph.D. as a Class III director of the Company, effective at the Effective Time.
In addition, on April 16, 2025, in connection with the Agreement, Franklin Berger informed the Board that he would retire following the end of his current term as a Class I director at the 2027 Annual Meeting.
On February 20, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Atea Pharmaceuticals, Inc. (the “Company”) elected Arthur Kirsch as a Class I director of the Company, effective immediately.
Max materiality 0.85 · Median 0.60 · Most common event earnings